Elevation Oncology expects that its cash, cash equivalents and marketable securities as of September 30, 2023, will be sufficient to fund its current operations into the second half of 2025. Upcoming 2024 milestones: Update from Ongoing Phase 1 Clinical Trial of EO-3021 Now Expected Mid-2024; Expanding EO-3021 Clinical Development Program to Include Combination Strategy; Announcing HER3-targeting ADC as Second Pipeline Program; Development Candidate Nomination in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
